SG11201900616UA - Engineered polypeptides and uses thereof - Google Patents

Engineered polypeptides and uses thereof

Info

Publication number
SG11201900616UA
SG11201900616UA SG11201900616UA SG11201900616UA SG11201900616UA SG 11201900616U A SG11201900616U A SG 11201900616UA SG 11201900616U A SG11201900616U A SG 11201900616UA SG 11201900616U A SG11201900616U A SG 11201900616UA SG 11201900616U A SG11201900616U A SG 11201900616UA
Authority
SG
Singapore
Prior art keywords
international
mutations
disclosed
pct
polypeptides
Prior art date
Application number
SG11201900616UA
Other languages
English (en)
Inventor
Karthik Viswanathan
Boopathy Ramakrishnan
Brain Booth
Kristin Narayan
Andrew Wollacott
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of SG11201900616UA publication Critical patent/SG11201900616UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
SG11201900616UA 2016-08-02 2017-08-02 Engineered polypeptides and uses thereof SG11201900616UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370201P 2016-08-02 2016-08-02
US201762485671P 2017-04-14 2017-04-14
PCT/US2017/045126 WO2018052556A1 (en) 2016-08-02 2017-08-02 Engineered polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
SG11201900616UA true SG11201900616UA (en) 2019-02-27

Family

ID=59656189

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900616UA SG11201900616UA (en) 2016-08-02 2017-08-02 Engineered polypeptides and uses thereof

Country Status (22)

Country Link
US (3) US11858980B2 (https=)
EP (1) EP3494134B1 (https=)
JP (2) JP7464389B2 (https=)
KR (2) KR102777127B1 (https=)
CN (3) CN118085091A (https=)
AU (2) AU2017325654B2 (https=)
BR (1) BR112019001989A2 (https=)
CA (1) CA3032820A1 (https=)
CL (3) CL2019000261A1 (https=)
CO (1) CO2019000931A2 (https=)
DK (1) DK3494134T3 (https=)
ES (1) ES3062797T3 (https=)
FI (1) FI3494134T3 (https=)
HR (1) HRP20260151T1 (https=)
IL (2) IL315729A (https=)
LT (1) LT3494134T (https=)
MX (1) MX2019001458A (https=)
NZ (1) NZ750257A (https=)
PT (1) PT3494134T (https=)
SG (1) SG11201900616UA (https=)
SI (1) SI3494134T1 (https=)
WO (1) WO2018052556A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013008697A2 (pt) 2010-09-24 2016-06-21 Massachusetts Inst Technology géis nanoestruturados capazes de liberação controlada de agentes encapsulados
HRP20260151T1 (hr) 2016-08-02 2026-03-27 Visterra, Inc. Modificirani polipeptidi i njihova uporaba
WO2018031258A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
WO2018031400A1 (en) * 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
US11020410B2 (en) 2017-02-03 2021-06-01 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
EP3710482A4 (en) * 2017-11-14 2021-08-18 University Of Virginia Patent Foundation COMPOSITIONS AND METHODS OF MANUFACTURING AND USING BISPECIFIC ANTIBODIES
IL276286B2 (en) * 2018-01-26 2025-07-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life
CN112543643A (zh) * 2018-03-05 2021-03-23 肿瘤免疫股份有限公司 使用可溶性cd24用于治疗获得性免疫缺陷综合征（hiv/aids）的方法
JP2021520352A (ja) 2018-04-04 2021-08-19 アリヴィオ セラピューティクス， インコーポレイテッド 生物製剤の制御送達用の自己組織化ゲルおよびその製造方法
WO2019235426A1 (ja) * 2018-06-04 2019-12-12 中外製薬株式会社 細胞質内での半減期が変化した抗原結合分子
WO2020051507A1 (en) 2018-09-06 2020-03-12 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
JP7410143B2 (ja) * 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途
EP3883968A4 (en) * 2018-11-22 2022-08-17 Agency for Science, Technology and Research MODIFIED FC REGION
SG11202104352XA (en) * 2018-12-18 2021-05-28 Boehringer Ingelheim Io Canada Inc Flt3 agonist antibodies and uses thereof
AR117453A1 (es) * 2018-12-20 2021-08-04 Genentech Inc Fc de anticuerpos modificados y métodos para utilizarlas
CN111978393B (zh) * 2019-05-23 2024-06-18 厦门大学 抗乙肝病毒新型抗体及其用途
MY210065A (en) 2019-06-17 2025-08-25 Visterra Inc Humanized antibody molecules to cd138 and uses thereof
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
EP4025596A4 (en) * 2019-09-04 2023-09-20 Cedars-Sinai Medical Center Use of calcineurin inhibitor free ctla4-ig + anti-il6/il6r for long term immunosuppression in solid organ transplant recipients
EP3819312A1 (en) * 2019-11-10 2021-05-12 Amgen, Inc Dosing regimen for anti-dll3 agents
WO2021119467A1 (en) 2019-12-11 2021-06-17 Visterra, Inc. Compositions and methods for treating and preventing influenza
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CN111254207A (zh) * 2020-01-22 2020-06-09 郑州大学第一附属医院 用于区别自身免疫性肝炎和健康人群的肠道微生物标志物及其应用
CA3187823A1 (en) 2020-06-24 2021-12-30 Visterra, Inc. Antibody molecules to april and uses thereof
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
TW202245825A (zh) 2021-01-20 2022-12-01 美商威特拉公司 介白素-2藥劑及其用途
EP4297796A1 (en) * 2021-02-25 2024-01-03 Cidara Therapeutics, Inc. Variant fc domains and uses thereof
TW202246339A (zh) * 2021-03-03 2022-12-01 愛爾蘭商赫萊森治療愛爾蘭公司 治療甲狀腺眼疾的方法
WO2023097254A1 (en) 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
AU2022399832A1 (en) 2021-12-01 2024-06-06 The Children's Hospital Of Philadelphia Methods of using interleukin-2 agents
CA3243493A1 (en) 2022-02-11 2023-08-17 Visterra, Inc. INTERLEUKIN-2 MUTEINS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
US20240092921A1 (en) 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof
CN115028738B (zh) * 2022-06-14 2025-05-16 天津医科大学 一种Fc融合蛋白双重靶向降解剂及应用
WO2024027793A1 (en) * 2022-08-05 2024-02-08 I-Mab Biopharma (Hangzhou) Co., Ltd. Bispecific antibodies targeting ifnar1 and blys
JP2025534759A (ja) * 2022-10-18 2025-10-17 クロスポイント セラピューティクス インコーポレイテッド ヒト抗体ｆｃドメイン変異体及びその用途
US20240150447A1 (en) * 2022-11-04 2024-05-09 Cephalon, LLC Compositions and methods for increasing transport into the brain
EP4680649A1 (en) * 2023-03-06 2026-01-21 Joint Stock Company "Biocad" Antibody-like molecule comprising heterodimer of human cd1b (cluster of differentiation 1) protein
WO2024211779A1 (en) * 2023-04-05 2024-10-10 The Regents Of The University Of California Affinity peptides for diagnosis and treatment of viral infections
CN120060370A (zh) * 2023-11-29 2025-05-30 上海科锐克医药科技有限公司 用于递送人vegf受体融合蛋白的基因递送载体及其应用
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025221954A1 (en) 2024-04-17 2025-10-23 Visterra, Inc. Use of il-2 variant for treating kidney transplant rejection
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1572091A4 (en) 2002-07-09 2008-03-05 Genentech Inc COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
AU2012203476A1 (en) * 2003-11-12 2012-07-05 Biogen Idec Ma Inc. Neonatal Fc Receptor (FcRn)-Binding Polypeptide Variants, Dimeric Fc Binding Proteins and Methods Related Thereto
SI1706424T1 (sl) 2004-01-12 2010-01-29 Applied Molecular Evolution Variante fc regij
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
AU2005285347A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8546543B2 (en) * 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP1858925A2 (en) * 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
WO2008030564A2 (en) 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
WO2008032833A1 (en) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
WO2008114011A2 (en) * 2007-03-19 2008-09-25 Medimmune Limited Fc polypeptide variants obtained by ribosome display methodology
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
JP5913980B2 (ja) * 2008-10-14 2016-05-11 ジェネンテック， インコーポレイテッド 免疫グロブリン変異体及びその用途
WO2010068722A1 (en) * 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
AU2015200990B2 (en) 2009-03-20 2016-07-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Optimized Fc variants
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
US9013699B2 (en) 2009-11-09 2015-04-21 Cantwell G. Carson Vaccine testing system
EP4012714A1 (en) 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
US20170039314A1 (en) 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
WO2012032080A1 (en) * 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
EP2647706B1 (en) * 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9505826B2 (en) 2010-12-22 2016-11-29 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
US8952132B2 (en) 2011-02-07 2015-02-10 Research Development Foundation Engineered immunoglobulin FC polypeptides
WO2012132067A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
MX2018012383A (es) 2011-03-30 2023-03-07 Chugai Pharmaceutical Co Ltd Método para alterar la retención en plasma e inmunogenicidad de la molécula de union al antígeno.
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
EP2752200B1 (en) 2011-09-30 2023-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
RU2014117505A (ru) 2011-09-30 2015-11-10 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула для ускорения удаления антигенов
KR20230143201A (ko) 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
JP6313712B2 (ja) 2011-12-21 2018-04-18 アムジエン・インコーポレーテツド 新生児Ｆｃ受容体への結合を強化された変異型Ｆｃポリペプチド
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
KR102148303B1 (ko) * 2012-02-11 2020-08-26 제넨테크, 인크. R-스폰딘 전위 및 그의 사용 방법
EP3738980A1 (en) 2012-02-24 2020-11-18 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc gamma riib
US10011660B2 (en) 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
EP2857419B1 (en) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
JP6280300B2 (ja) 2012-08-24 2018-02-14 中外製薬株式会社 脳疾患治療剤
US20140294812A1 (en) 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
UA118029C2 (uk) * 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
ES2869459T3 (es) * 2014-05-16 2021-10-25 Medimmune Llc Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas
KR20170015920A (ko) 2014-06-12 2017-02-10 에프. 호프만-라 로슈 아게 ＦｃＲｎ 상호작용이 변화된 항체를 선별하는 방법
FR3024453B1 (fr) 2014-08-01 2018-06-29 Lab Francais Du Fractionnement Procede de production de variants ayant un fc presentant une sialylation amelioree
DK3215528T3 (da) * 2014-11-06 2019-10-07 Hoffmann La Roche Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
KR20180002653A (ko) * 2015-04-07 2018-01-08 제넨테크, 인크. 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
FR3035879B1 (fr) 2015-05-07 2025-02-28 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle modifiee
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
CA3011887C (en) 2016-03-14 2024-10-29 Universitetet I Oslo Genetically transformed immunoglobulins with altered FCRN binding
US20170298119A1 (en) * 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
HRP20260151T1 (hr) 2016-08-02 2026-03-27 Visterra, Inc. Modificirani polipeptidi i njihova uporaba
EP4424707A3 (en) 2017-09-19 2024-11-13 Tillotts Pharma AG Antibody variants

Also Published As

Publication number Publication date
EP3494134A1 (en) 2019-06-12
EP3494134B1 (en) 2025-12-10
CL2024003234A1 (es) 2025-03-07
IL315729A (en) 2024-11-01
CN110072887A (zh) 2019-07-30
SI3494134T1 (sl) 2026-04-30
FI3494134T3 (fi) 2026-02-19
JP2022120132A (ja) 2022-08-17
CL2019000261A1 (es) 2019-06-28
US20250296982A1 (en) 2025-09-25
IL264590A (en) 2019-02-28
LT3494134T (lt) 2026-02-25
PT3494134T (pt) 2026-03-02
KR20190038607A (ko) 2019-04-08
AU2024270619A1 (en) 2025-01-02
CN118388638A (zh) 2024-07-26
CL2022000036A1 (es) 2022-10-28
WO2018052556A8 (en) 2019-03-14
DK3494134T3 (da) 2026-02-09
RU2019104889A3 (https=) 2020-09-04
US20200277358A1 (en) 2020-09-03
WO2018052556A1 (en) 2018-03-22
AU2017325654A1 (en) 2019-02-14
IL264590B1 (en) 2025-12-01
KR102777127B1 (ko) 2025-03-07
US20180037634A1 (en) 2018-02-08
KR20250036943A (ko) 2025-03-14
NZ750257A (en) 2026-02-27
MX2019001458A (es) 2019-07-04
JP7464389B2 (ja) 2024-04-09
ES3062797T3 (en) 2026-04-14
US11858980B2 (en) 2024-01-02
HRP20260151T1 (hr) 2026-03-27
CA3032820A1 (en) 2018-03-22
IL264590B2 (en) 2026-04-01
CN118085091A (zh) 2024-05-28
BR112019001989A2 (pt) 2019-08-20
CO2019000931A2 (es) 2019-02-08
JP2019531705A (ja) 2019-11-07
RU2019104889A (ru) 2020-09-04
AU2017325654B2 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
SG11201900616UA (en) Engineered polypeptides and uses thereof
SG11201804857WA (en) Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
SG11201907422RA (en) Anti-tau antibodies and methods of use thereof
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201903835WA (en) Antibodies directed against programmed death- 1 (pd-1)
SG11201809649WA (en) Macromolecule analysis employing nucleic acid encoding
SG11201906341XA (en) Improved serum albumin binders
SG11201903302UA (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
SG11201909048TA (en) Use of klk5 antagonists for treatment of a disease
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201810687SA (en) Serum albumin-binding fibronectin type iii domains
SG11201907638QA (en) Proteins binding cd33, nkg2d and cd16
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201808261RA (en) Genetic variant-phenotype analysis system and methods of use
SG11201900815UA (en) Expression of pten-long with ocolytic viruses
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof